1 / 27

B iomarkers of I njury and O utcome in ProTECT III

B iomarkers of I njury and O utcome in ProTECT III. NIH/NINDS: 1R01NS071867 PI: Michael Frankel Emory University. Prognosis in moderate (GCS 9-12) or severe TBI (GCS 4-8). Prior studies Retrospective design Small cohorts Combining multiple studies No prospective validation of outcome.

aitana
Download Presentation

B iomarkers of I njury and O utcome in ProTECT III

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Biomarkers of Injury and Outcome inProTECT III NIH/NINDS: 1R01NS071867 PI: Michael Frankel Emory University

  2. Prognosis in moderate (GCS 9-12) or severe TBI (GCS 4-8) • Prior studies • Retrospective design • Small cohorts • Combining multiple studies • No prospective validation of outcome

  3. Structrual Biomarkers in TBI • Release of structural proteins into the bloodstream • S100B protein (S100B) • GlialFibrillary Acidic Protein (GFAP) • Alpha-2 Spectrin Breakdown Products (SBDP150) • Ubiquitin C-hydrolase (UCH-L1) • Serum blood levels may correlate with extent of brain injury • Could serve as useful markers of the severity of the injury • May provide useful information about response to treatment. • None of these biomarkers have been prospectively validated to assess their clinical utility.

  4. S100B, GFAP, UCH-L1 • S100B is a calcium binding protein in astroglia, oligodendrocytes, and Schwann cells. • GFAP is a monomeric intermediate filament protein derived from the astroglial cytoskeleton • Ubiquitin C-hydrolase (UCH-L1) is a protein that is almost exclusively found in neurons. It maintains ubiquitin homeostasis and is released into the blood stream after TBI.

  5. αII-Spectrin • αII-Spectrin is a structural protein in the neuronal cytoskeleton. It is found in neuronal cell bodies, axons and pre-synaptic terminals. Calpain and caspase-3 degrade αII-spectrin into breakdown products via necrosis and apoptosis cell death pathways, respectively. In TBI, calcium entry into neurons triggers calpain mediated proteolysis of αII-Spectrin creating two αII-Spectrin breakdown products (SBDPs) with molecular weights of 150 and 145 kDA. Caspase-3 also produces two SBDPs with molecular weights of 150 and 120 kDA.

  6. BIO-ProTECTBiomarkers of Injury Outcomes in the ProTECT III Clinical TrialMichael Frankel (PI) Goal: Examine the utility of serum biomarkers as a tool to reliably assess injury severity and to guide treatment decisions in acute TBI patients. Primary Aim: To determine whether serum biomarkers of structural brain injury (S100B, GFAP, UCH-L1, SBDP150) are independent predictors of clinical outcome assessed 6 months after moderate or severe acute TBI. Secondary Aim:To define the relationship between steady state serum progesterone levels and treatment effect after moderate or severe acute TBI.

  7. Hypotheses • Hypothesis 1: Elevated levels of serum biomarkers (S100B, GFAP, UCH-L1, SBDP150), measured within 4 hours of TBI, are independent predictors of outcome as measured by the Glasgow Outcome Scale Extended (GOS-E) at 6 months. • Hypothesis 2: Elevated levels of serum biomarkers (S100B, GFAP, UCH-L1, SBDP150), measured 24 and 48 hours after study randomization, are independent predictors of outcome as measured by the GOS-E at 6 months.

  8. Hypotheses • Hypothesis 3: In progesterone-treated subjects, steady state serum progesterone levels measured 24 hours after study randomization will: • a) inversely correlate with biomarker levels at 24 hours and • b) directly correlate with a favorable outcome as measured by the GOS-E at 6 months.

  9. Analysis: Hypothesis 1 • Using a two-step analysis plan to develop and validate a predictive model that incorporates baseline biomarker and clinical data (obtained within 4 hours of TBI), we will develop a prognostic model (using half of the subjects within the treatment and control arms of ProTECT III) to predict outcome on the GOS-E, and to validate this model using data from the other half of the subjects within each arm of ProTECT III.

  10. Analysis: Hypothesis 2 • Using a two-step analysis plan to develop and validate a predictive model that incorporates baseline biomarker and clinical data (obtained at 24 and 48 hours after TBI), we will develop a prognostic model (using half of the subjects within the treatment and control arms of ProTECT III) to predict outcome on the GOS-E, and to validate this model using data from the other half of the subjects within each arm of ProTECT III.

  11. Analysis: Hypothesis 3 • In progesterone-treated subjects, determine whether steady state serum progesterone levels inversely correlate with serum levels of S100B, GFAP, UCH-L1, SBDP150 (24 and 48 hours after study randomization) and correlate directly with a favorable outcome of progesterone treatment at 6 months

  12. Clinical Utility • Improve risk stratification • Improve treatment decisions • Surrogate or proxy marker of treatment response • Gain further insight into the pathophysiology of TBI

  13. Consent • All ProTECT III subjects • Single consent form • EFIC • Withdrawal of participation

  14. Lab Kits • Lab kits will include the following supplies necessary for all 3 blood draws, as well as for specimen transport via FedEx. • Insulated Shipping Box x 1 • Corrugated cardboard box x 1 • Disposable Styrofoam rack for sample storage and transport x 1 • Disposable transfer pipette x 4 • 10 ml Tiger Top tubes x 6 (2 per draw x 3 draws) • Aliquot tubes (cryovials) x 24 (8 per draw x 3 draws) • Shipping bags x 4 • Specimen labels x 30 • Core Laboratory Shipment Form • FedEx Airbill

  15. Lab Kits - Supplies • To obtain additional lab kits: • Kit supplies will automatically be replenished based upon enrollment activities, but if you are down to only two kits, send an e-mail request to protectsupplies@emory.edu to ensure that you have at least one box on hand at all times.

  16. Specimen Handling (at Baseline, 24 and 48 hours) • Fill two10ml tiger top tubes • Gently invert the tube 5 times to provide adequate mixing with the clotting activator. Avoid hemolyzing the blood. • Put patient study ID, date, time of draw, and your initials on label for the tiger top tubes and the aliquot tubes. • Place specimen tube upright in the disposable Styrofoam tube holder provided and allow to clot at room temperature for a minimum of 30 minutes and maximum of 120 minutes. • Transport blood sample in Styrofoam tube holder to processing lab NOTE: Keep samples upright at all times

  17. Specimen Processing vs • Centrifuge specimen at room temperature. • Spin sample at 1200 RCF (g) for: • 15 minutes if fixed angle centrifuge rotor or • 10 minutes if using a horizontal (sling) rotor • Carefully remove tube from the centrifuge. The serum (clear yellowish liquid) will be on top of the clotted red cells. DO NOT shake or invert specimen tube after centrifuging to avoid disturbing the cell palate on the bottom of the tube. • Using the pipette, very carefully remove the clear serum, avoiding any of the red cells. If you accidently get red cells in the pipette, gently return the contents of the pipette into the specimen tube, re-spin for 15 minutes, and pipette again.

  18. Divide the serum equally between the 8 aliquot tubes (4 aliquot tubes for each tiger top tube of blood obtained) and put caps on the aliquot tubes tightly . Place all aliquot tubes into the corrugated cardboard box and freeze specimens immediately at - 80° C, until ready to ship.

  19. Tracking form for shipping is in WebDCU It is key to properly label TUBES (Patient ID, Date, Time, etc) through out the process so that tubes do not get mixed up. Sample Tracking for Shipping

  20. Packaging for Shipment • Once all three sets of specimens (Baseline, 24 and 48 hours) are thoroughly frozen, prepare for shipment as follows: • Secure the lid on corrugated cardboard box with tape or rubber band. • Place corrugated cardboard box into the specimen bag and seal. • Fill Styrofoam shipping box with dry ice. • Place the specimen bag into the insulated Styrofoam shipping box with dry ice. • Place the Styrofoam box into FedEx box and seal. • Include Forms in shipment (retain copy for file at local site)

  21. Shipping • Complete a Core Laboratory Shipment Form making sure the tracking number from the FedEx shipping label is completed. • Place the Core Laboratory Shipment Form and the Fed-ex airbill into the pouch and adhere to outside of box. • Send Priority Overnight Monday through Wednesday only (we want to avoid Saturday deliveries). If specimens are drawn on Thursday or Friday, keep frozen over the weekend and ship the following Monday. • FedEx shipping label will indicate shipment to: •  Banyan Biomarker, Inc • Attn : Jixiang Mo Seany • 13709 Progress Blvd. • Alachua, FL 32615 • 386-518-6736 (office) • 386-518-6794 (fax)

  22. All specimens must be spun, separated, aliquoted and frozen within 2 hours of collection. • Samples can be stored in a -80 freezer for up to one month, but should be mailed to the Core Laboratory at Banyan Biomarker, Inc, at the earliest possible opportunity (ship on Monday, Tues, or Wednesday) • Multiple subject specimens can be shipped together, but a separate corrugated cardboard box and specimen bag should be used for each subject

  23. Problems • Contact Bethany Lane, ProTECT III Project Manager or send an e-mail to protectsupplies@emory.edu. If urgent, call the ProTECT III Hotline at 888-359-2221.

  24. Emory University Michael Frankel (PI) David Wright Bethany Lane Don Denson James Ritchie MUSC Sharon Yeatts Yuko Palesch Bethany Wolf NETT Steering Committee Banyan Biomarkers, Inc. Kim Yates Juan Martinez ProTECT III sites UPMC Amy Wagner Radboud University – Netherlands Pieter Vos

More Related